Skip to main content
Equibles
SLDB logo

SLDB · Solid Biosciences Inc. · Metrics

Track SLDB — free

Use SLDB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SLDB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.43 +0.51 (+8.62%)
Russell 2000 member Rebalance outlook locked
Market Cap
$634.77M
Shares
107.23M
Volume · Oct 20 295.94K Avg daily vol (3M) 1.15M

SLDB metrics

67 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.92
Market cap
$634.77M

Price action

20 metrics
Price change (1W)
-11.8%
Price change (30D)
-30.7%
Price change (3M)
-29.9%
Price change (6M)
-30.3%
Price change (YTD)
+5.0%
Price change (1Y)
+0.7%
Trailing year
Price change (5Y)
—
52-week high
$11.15
52-week low
$3.93
Change from 52-week high
-46.9%
Change from 52-week low
+50.6%
Annualized volatility
78.7%
Annualized volatility (3M)
64.4%
Beta
2.2
RSI (14D)
32.8
Price vs SMA 50
-28.9%
Price vs SMA 200
-22.3%
Avg volume (3M)
1.15M
Relative volume
1.6
Average dollar volume
$9.27M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
107.23M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.6
reciprocal yield 63.1%
FCF yield
-31.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-34.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-02-18

Profitability

9 metrics
Gross margin
—
Operating margin
-1,315.2%
Trailing 12 months
Net margin
-1,062.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$212.15M
Net income (TTM)
−$207.10M
Trailing 12 months
Diluted EPS (TTM)
$-1.88
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.95
EBITDA per diluted share (TTM)
$-1.94
Net income per diluted share (TTM)
$-1.91
Operating cash flow per diluted share (TTM)
$-1.72
Free cash flow per diluted share (TTM)
$-1.73
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.54
Stock compensation per diluted share (TTM)
$0.20
Book value per share
$2.28

Growth

11 metrics
Revenue growth YoY
-40.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+52.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-55.4%
Return on assets
-49.2%
Debt / equity
0.0
Current ratio
13.8
EBITDA (TTM)
−$210.52M
Free cash flow (TTM)
−$187.81M
Quick ratio
13.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$159.39M
Latest balance sheet
Cash & equivalents
$159.39M
Total assets
$420.58M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$186.84M
Capital expenditures (TTM)
$965,000
R&D (TTM)
$167.40M
SG&A (TTM)
—
Stock compensation (TTM)
$21.20M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
156
13F filer change QoQ
+5
Institutional ownership
107.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.4%

Short interest

3 metrics
Short interest
11.9%
Latest settlement · 7.7 days to cover
Days to cover
7.7d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1707502 CUSIP 83422E204 13F (30d) 10 filings 10 filers Visit website Investor relations